NEWS
Paul Hastings Advises ACEA Therapeutics on Its Stock Acquisition Agreement With Phoenix Asia
May 06, 2026
Paul Hastings LLP advised ACEA Therapeutics Inc., a clinical stage pharmaceutical company, in its signing of a stock acquisition agreement with Phoenix Asia Holdings Limited (Nasdaq: PHOE). Pursuant to the agreement, Phoenix Asia agreed to purchase 100% of the issued and outstanding equity interests of ACEA Pharma Inc., a wholly owned subsidiary of ACEA Therapeutics, in exchange for the delivery to ACEA Therapeutics of 100,000,000 newly issued ordinary shares of Phoenix Asia, the value of which was as agreed by the parties to be $1 billion. The parties anticipate closing in Q2 of 2026.
Partners Jeff Hartlin and Elizabeth Razzano led the Paul Hastings team, which also included partner Lucas Rachuba and associates Mark Cramer, Daniel Jun, Pranav Iyer, Kelsey Massey and Hugh Malesh.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.